Formoterol protects against platelet-activating factor-induced effects in asthma.

@article{Gabrijelcic2004FormoterolPA,
  title={Formoterol protects against platelet-activating factor-induced effects in asthma.},
  author={J Gabrijelcic and Alejandro Casas and Roberto A Rabinovich and Josep Roca and Joan Albert Barber{\`a} and Kian Fan Chung and Roberto Rodr{\'i}guez-Rois{\'i}n},
  journal={The European respiratory journal},
  year={2004},
  volume={23 1},
  pages={71-5}
}
Platelet-activating factor (PAF) is an inflammatory mediator that provokes neutropaenia, bronchoconstriction and gas exchange defects due to exudation of bulk plasma within the airways. While the inhibitory effects of short-acting beta2-agonists on PAF-induced disturbances have been consistently shown, those of long-acting beta2-agonists are less convincing. To further explore the mechanisms involved in PAF challenge in asthma, 12 patients (forced expiratory volume in one second, 90 +/- 4… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Formoterol protects against the neutropenia induced by platelet activating factor in humans (abstract)

  • SJ Wort, BH Shakur, P. Ind
  • Eur Respir J 1998; 12: Suppl
  • 1998

Similar Papers

Loading similar papers…